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revealed remarkable GR-dependent cooperation between CpdA
and Bortezomib in suppressing survival of lymphoma cells
in vitro and in vivo. Also surprising findings were substantial
cooperation in anti-cancer effect of immunosuppressant Rapa-
mycin and CpdA in vitro, and unexpected ‘‘dissociated” effect of
Rapamycin on GR signaling realized through down -regulation
of REDD1, mTORC1 inhibitor. These data suggested high clinical
potential of Rapamycin/GC combination in cancer treatment.
(2) SEGRA list extention
We used two approaches to extend SEGRA list: (1) synthesis of
CpdA enantiomers and (2) its chemical derivatives. Chemical
analogues of CpdA were designed by appending of bulky sub-
stituent into benzene ring, alkylation of carbon atom adjacent
to chlorine atom or appending of substituents to nitrogen atom.
Evaluation of biological properties of enantiomers revealed
higher GR-dependent anti-cancer potential of S-CpdA. Cytotoxic
and proapoptotic effects of CpdA analogues were comparable
with precursor.
(3) Selection of tumor types acceptable for SEGRA treatment.
CpdAwas selected for NCI-60 in Vitro Cell Line Screening Pro-
ject providing direct support to anticancer drug discovery pro-
gram. It was shown that CpdA affect viability of some adherent
cancer cell lines. We demonstrated that CpdA unlike GCs did
not modify microenvironment and disintegrate tight junctions
between cells decreasing risk of metastasis in case of solid
tumors. It demonstrates reasonability of further investigations.
Overall, our data provide the rationale for novel therapy of
cancer based on combination of non-steroidal GR modulators
with classic and modern chemotherapeutics. Approaches to
obtain more SEGRAs were elaborated.
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Background: There are numerous evidences suggesting that
tumor evolution follows the laws of Darwinian evolution,
whereby individual tumor cell clones have private genetic
aberrations, including chromosomal abnormalities. The
combined effect of genetic instability and differential selective
pressures of the microenvironment and chemotherapy can result
in the creation of new tumor clones (Navin et al., 2011; Ng et al.,
2012). The aim of this study is to show breast tumor clonal evolu-
tion during neoadjuvant chemotherapy (NAC) using microarray
analysis.
Material and methods: Breast cancer patients (n = 26) with
stage IIA to IIIC (T1-4N0-3M0), were treated with NAC (FAC or
CAX regimens). DNA was extracted from 26 samples of tumor
tissue derived before or after NAC using QIAamp DNA mini Kit
(Qiagen, Germany). Copy Number Aberrations (CNA, deletions
and amplifications, or Loss and Gain, respectively) and number
of mutant clones were detected in pre- and post-NAC tumor
samples using the high density microarray platform Affymetrix
(USA) CytoScanTM HD Array. This study was approved by Tomsk
Cancer Research Institute review board.
Results: We have revealed that 19% (5/26) of patients during the
NACshowed thedecrease in thenumberofmutant clones andCNA
frequency right up to their complete elimination (genetic
regression) at one case. In 7 (27%) cases chemotherapy had no
any effect on number of mutant clones and the frequency of CNA
in tumor. In the tumors of 10 patients the elimination of some
mutant clones aswell as the formation of new cloneswith deleted
genetic material occurred under the influence of chemotherapy. 6
patients have demonstrated the appearance of new tumor clones
with gene amplificationswhich were associatedwith the develop-
ment of metastases in 83% of cases (5/6). All other patients (n = 21)
who has not acquired the new tumor clones with Gain function
mutation after NAC did not manifest distant metastasis in 5-year
follow-up (Kaplan–Meier, p = 0.00001 Log-rank test).
Conclusion: The first time evidence is presented that the for-
mation of new tumor clones may occur during the NAC. Metasta-
sis of breast cancer is associated with the appearance of new
clones with DNA amplifications. Detection of these clones allow
getting new prognostic factor in breast cancer.
The study was supported by the Russian Foundation for Basic
Research – Russia (Project 15-04-03091).
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Cutaneous melanoma is one of the most aggressive human
neoplasms that can quickly metastasize to regional lymph nodes.
Currently, prognosis is determined by measuring tumor thickness
but more reliable markers for metastatic spread are urgently
needed. It is well known that tumors require a microvasculature
development in order to grow and metastasize. Angiogenesis
and lymphangiogenesis play an important role not only in the
tumor growth, but also in the tumor metastasis. As malignancy
is a disorder of cellular growth control, the assessment of cell
proliferation rates in tumors has intuitive appeal as a prognostic
marker. One such biomarker is Ki-67, a cell cycle dependent
protein. Recent reports related to its role as a prognostic factor
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have been contradictory. The purpose of this study was to inves-
tigate lymphangiogenesis, angiogenesis and tumor tissue prolif-
erative activity depending on the clinical stages of melanoma.
The objects of the study were the samples of tumor tissue
obtained during surgical treatment of cutaneous malignant mel-
anoma. To analyze tumor angiogenesis, lymphangiogenesis and
proliferation, we performed immunostains of the primary mela-
nomas for the vascular marker CD34, for the lymphatic-specific
markers LYVE-1, D2 -40 (Podoplanin) and marker of proliferation
– Ki-67. Samples of tumor tissue from 40 patients with IA, IB,
IIA, IIB, IIIC melanoma stages were fixed in 10% neutral formalin,
processed by standard histological techniques and embedded in
paraffin. All steps of the immunohistochemical reaction were per-
formed by using BENCHMARK/XT slide stainer (Ventana).
Determination of blood vessel volume density revealed its
growth an average of 2 times in peritumoral areas. Similar data
were obtained about the location lymphatic vessels. Greater con-
tent peritumoral blood and lymphatic vessels, then intratumoral
could be detected in all stages of melanoma. In addition more sig-
nificantly greater volume density both intratumoral and peritu-
moral blood vessels, than lymphatic vessels was found. A
greater degree expression of endothelium lymphatic vessels
markers Podoplanin, compared with the LYVE-1 was shown. It
was noted an increasing volume density of the peritumoral blood
and lymphatic vessels in primary tumors with expansion clinical
stage melanoma. Three levels of proliferative activity of tumor
tissue were determined (low, an average degree and high Ki-67
expression). Results of the analysis have shown, that the high
proliferative activity corresponded to significant content of blood
and lymphatic vessels. High level of these markers was observed
in patients with regional lymph nodes metastases.
In recent years there have been appeared publications sug-
gesting that lymphatic vessel density (particularly in a peritu-
moral location) and lymphatic vessel invasion are predictors of
sentinel node metastasis and poorer survival. It was noted, that
‘‘larger, carefully conducted and well-reported studies that con-
firm these preliminary findings are required before it would be
appropriate to recommend the routine application of costly and
time-consuming immunohistochemistry for lymphatic markers
in the routine clinical assessment of primary cutaneous
melanomas”. In our opinion, one must consider not only the
lymphatic vessels density, but also blood vessels, and the tumor
tissue proliferative activity.
Conclusion: This study has shown that the complex markers of
lymphangiogenesis (Podoplanin), angiogenesis (CD34) and prolif-
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Background: Earlier we showed that at least some of nucleo-
tide sequences with tumor-specific expression are evolutionary
novel (reviewed in [A.P. Kozlov, 2014]). In this paper we per-
formed the study of the relative evolutionary novelty of human
oncogenes, all protein-coding genes, genes encoding tumor
antigens, tumor suppressors and tumor-associated genes using
homology searches in genomes of different taxa in human
lineage.
Materials and methods: The following databases were used as
a source of human genes: oncogenes – COSMIC (574 genes), tumor
suppressors – TSGene (636 genes), all tumor-associated genes –
allOnco (2116 genes) and NCG (2001 genes), cancer-testis (CT)
antigen genes – CTDatabase (276 genes) and all annotated human
protein coding genes – Genome assembly GRCh38 (21694 genes).
The list of cancer vaccine antigen genes was retrieved from paper
of Cheever et al., 2007, where 75 cancer antigens were ranked
according to their potential suitability for anticancer vaccines.
Some of cancer antigens are non-protein molecules, mutant or
fusion-proteins. Thus, we examined the evolutionary novelty of
only 58 protein-coding cancer vaccine antigen genes. To
analyze the evolutionary novelty of the explored genes the
HomoloGene release 68 tool and ProteinHistorian tool were
used. The HomoloGene tool searches the orthologs in 11 taxa of
the human lineage (Eukaryota, Opisthokonta, Bilateria,
Euteleostomi, Tetrapoda, Amniota, Boreoeutheria, Euarchon-
toglires Catarrhini, Homininae, H.sapiens) and the ProteinHisto-
rian tool searches the orthologs in 16 taxa of the human
ligeage (Cellular Organisms, Eukaryota, Opisthokonta, Bilateria,
Deuterostomia, Chordata, Euteleostomi, Tetrapoda, Amniota,
Mammalia, Theria, Eutheria, Euarchontoglires, Catarrhini,
Homininae, H.sapiens). To analyze the statistical significance of
data Fisher’s exact test was used.
Results: Several curves of taxonomic distribution of ortho-
logs of different classes of human genes have been generated.
A set of curves forms a peculiar picture where different curves
are organized in a definite order. The curves never intersect
after Bilateria. The uppermost position occupies the curve
which describes the oncogene orthologs distribution. Right
below the oncogene curve, the distribution curve of tumor
suppressor genes orthologs taxonomic is located, and the dif-
ference between these curves is significant. The distribution
curves of other tumor-associated genes orthologs overlap with
tumor suppressor curve. The medium position in the whole
picture is occupied by the distribution curve of orthologs of
all human protein-coding genes. Below this curve the distribu-
tion curves of orthologs of different tumor antigens are
located. The first below the medium curve is tumor vaccine
antigen curve, then CT and CT-X antigen genes orthologs
distribution curves are located. Thus at any given timepoint
the relative proportion of oncogene orthologs described by
distribution curve is higher than of any other studied class
of human genes.
Conclusion: 1. The evolution of human oncogenome advances
ahead of all other human gene classes. 2. On the other hand, the
evolution of tumor antigen gene classes goes behind the rest of
human gene classes, i.e. tumor antigens genome is more evolu-
tionary novel.
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